Expert Warns Cosmetic IV Iron Marketing Risks Bone Softening, Fractures
Marketing intravenous iron infusions for cosmetic freshness and fatigue without a clinical diagnosis risks causing osteomalacia and bone fractures, an infectious disease consultant warned according to Alyaum.
He said it is being marketed as a quick way to get rid of tiredness and fatigue and restore activity and freshness without a sufficient evaluation of actual medical need, noting that complications from some of its preparations can reach the point of bone softening and fractures.
He emphasized that there is a difference between diagnosing iron deficiency and determining the most appropriate way to treat it.
Concerns regarding intravenous iron use returned to the forefront following the U.S. Food and Drug Administration’s addition of a boxed warning in September 2026 to the preparation Ferric Carboxymaltose, commercially known as Ferinject or Injectafer, due to the risks of low blood phosphate levels, according to Alyaum.
Phosphate deficiency can lead to severe muscle weakness, bone pain, osteomalacia, and fractures, especially with continued deficiency or repeated doses, and can occur even after a single dose and in people without clear risk factors.
The preparation is linked to increased activity of the FGF23 hormone, which prompts the kidneys to get rid of phosphate through urine and affects vitamin D metabolism, potentially leading to persistently low phosphate levels.
He added that repeating doses without reassessing treatment need, failing to account for safety differences among intravenous iron preparations, and marketing it as a cosmetic procedure or energy-boosting method are practices that require review.
Intravenous iron remains the most appropriate choice in cases including oral iron intolerance, poor absorption, the need for rapid replenishment, and certain kidney, heart, and intestinal disease cases according to approved medical guidelines.